The complexity of drug reconstitution has for many decades constrained the market potential for lyophilized drugs and vaccines. With multiple pieces of equipment and around a dozen non-intuitive steps required to reconstitute a lyophilized drug from a vial, the overwhelming majority of these products are restricted to administration within healthcare facilities. However, the healthcare shift toward patient self-injection and the accelerating momentum behind biologics has sparked a new wave of innovation for drug reconstitution technology. Dual-chamber syringes in particular represent an enabling technology not only for the self-injection of lyophilized drugs, but also other emerging therapies requiring the mixing of two liquid molecules at the time of delivery. More than 300 approved drugs and vaccines requiring reconstitution or mixing are currently marketed for use within the US. By some estimates, between one-quarter and one-third of all FDA approvals in recent years have been for parenteral drugs supplied in a lyophilized format. For some of these drugs and vaccines, lyophilization represents the fastest route to market, with pharmaceutical companies later planning their introduction in an alternative format as part of lifecycle management strategies.